| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514588000 | Ureas (i.e., N-C(=O)-N) | 66 |
| 20080293818 | Regulator of Physiological Function of Ghrelin and Use Thereof - A regulator for regulating physiological functions, such as activity of increasing an intracellular calcium ion concentration, activity of promoting growth hormone secretion, activity of promoting eating, regulatory activity relating to fat accumulation, activity of ameliorating heart function and activity of stimulating gastric acid secretion, of ghrelin, which regulator comprises a fatty acid of carbon number 2-35 or its derivative, and use thereof. | 11-27-2008 |
| 20090197964 | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage - Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. | 08-06-2009 |
| 20090312428 | Biocide Compositions Comprising Quaternary Ammonium and Urea and Methods for Their Use - Composition and method for treating and/or preventing biological contamination using a biocide composition comprising at least one quaternary ammonium compound and urea. The method includes drying urea, and thereafter combining at least one quaternary ammonium compound and urea and may produce a potent biocide composition that is stable and able to chemically treat biological contamination in a variety of difficult to reach locations. Uses of the composition are also described. | 12-17-2009 |
| 20100010091 | Anhydrous, Dermatological or Cosmetic Preparation Containing Urea - A dermatological or cosmetic preparation, which is anhydrous and contains urea, and is administered to improve the water retention capability of the stratum corneum, contains phytantriol and comprises a gel-like basis, which is essentially free of straight-chained hydrocarbons with 6 to 50 C-atoms. Compared with known such preparations, the preparation comprises markedly improved dermal sensory attributes. | 01-14-2010 |
| 20100240759 | USE OF AN AGENT THAT CONTAINS CORBAMIDE AND/OR AT LEAST A DERIVATIVE THEREOF AS A CLEANING AGENT - The invention relates to the use of an agent that contains 5 to 99.9% in weight of carbamide and/or at least a derivative thereof, as a cleaning agent for closed systems, in particular as a dishwasher detergent, as a laundry detergent for washing machines, as an agent for cleaning, sanitizing and/or disinfecting for equipment in the food processing industry and for medical equipment, the use as a hand dishwashing detergent or sanitary cleaner or as a hand cleaner. In addition, the invention relates to a method for reducing or avoiding enzymes in cleaning agents for closed systems, in hand dishwashing detergents or in sanitary cleaning agents as well as an enzyme-free dishwashing detergent or enzyme-free sanitary cleaning agent that contain 5 to 99.9% in weight of carbamides or derivates thereof. Finally, the invention relates to the use of percarbamide as a bleaching agent in particular in dishwashing detergents and in sanitary toilet cleaning agents. | 09-23-2010 |
| 20100331416 | Use of Monochlorourea to Treat Industrial Waters - The present invention comprises a method for controlling (e.g. inhibiting) or killing microorganisms in an aqueous environment. The method includes the addition of an effective amount of monochlorourea or modified monochlorourea to an aqueous solution. This aqueous solution may be a cooling water system, a recreational water system, a water treatment facility, or any circulating water system (i.e. a papermaking facility). A method of producing monochlorourea or modified monochlorourea is also disclosed. | 12-30-2010 |
| 20110028559 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS - Treating pain in mammals with a compound having the formula (I) is disclosed herein. | 02-03-2011 |
| 20120101165 | Urea Compositions With Cooling Effect - The present invention includes a urea powder, the particles of which are protected in a dimethicone and silica mixture, prior to being incorporated into anhydrous compositions. The protected urea is capable of imparting a cooling activity to a topical composition. The invention also pertains to topical, cooling compositions containing a protected urea. The use of the protected urea to impart a cooling activity to topical anhydrous compositions is new. Topical, anhydrous compositions comprising the protected urea are also new. Anhydrous compositions containing the protected urea are stable against hydrolysis that might otherwise occur due to the ambient humidity. Disclosed compositions create a clean and fresh feel for a user. | 04-26-2012 |
| 20120129942 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTION OF THE NAIL - A stable antifungal composition for topical application on a nail comprising a diol component, an organic acid component, a volatile vehicle, an antifungal agent and a keratolytic agent; the active compound and the keratolytic agent are soluble in the composition in the absence of said volatile vehicle, and wherein at least one in the group selected from the antifungal agent and the keratolytic agent is present in solid state in the composition in the presence of said volatile vehicle. Preferred ingredients include propylene glycol, lactic acid, ethyl acetate, urea and terbinafine or naftifine. | 05-24-2012 |
| 20120178816 | CARBAMIDE PEROXIDE TREATMENTS FOR THE REPRODUCTIVE TRACT - Disclosed are methods of maintaining fertility or treating retained placenta, reproductive tract infection, or reproductive tract inflammation in an animal by administering carbamide peroxide to the reproductive tract of the animal. The carbamide peroxide administration removes placental remains on the uterine wall, protects against or treats reproductive tract infection, and protects against or treats reproductive tract inflammation such as metritis, and thereby maintains fertility in the animal. | 07-12-2012 |
| 20120196937 | TREATMENT OF OPHTHALMIC DISORDERS USING UREA - Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects. | 08-02-2012 |
| 20130012590 | SUBCUTANEOUS FAT REDUCTION - Topical dermatological preparations including one or more lipodissolving, lipolytic, or adipocyte-disrupting substances for treatment of localized adiposity can include carbamide peroxide and a terpene such as d-limonene. In some embodiments, the preparations can include carbamide peroxide as a first component and, as a second component, at least one peppermint oil terpene, peppermint oil, or a compound isolated or derived from peppermint oil. | 01-10-2013 |
| 20130137773 | Chelator Stabilized Cationic Ammonium Compounds and Compositions Comprising the Same - Stabilized cationic ammonium compounds are described. The compounds are stabilized with pyridine-based chelators and/or heteroketo-based chelators that impede the generation of nitrogen comprising groups from the cationic ammonium compounds. | 05-30-2013 |
| 20130178532 | METHOD FOR PREPARING BROMOUREA - The invention provides a process for manufacturing biocidal compositions containing bromourea derivatives, including the reaction of salts or adducts of the urea derivatives with an oxidizer. | 07-11-2013 |
| 20140018432 | ELECTROCHEMICAL GENERATION OF CHLORINATED UREA DERIVATIVES - Method of single step electrochemical generation of chlorinated urea, chlorinated dimethylurea and other chlorourea derivatives is disclosed. The chlorinated species are generated in situ and upon demand and can be used for microbial control in industrial water treatment. | 01-16-2014 |
| 20140288182 | USE OF CARBAMIDE PEROXIDE INJECTION IN PREPARATION OF VIRUS INACTIVATION MEDICAMENTS FOR TREATING DISEASES - The invention relates to the field of medicament use, in particular to the clinical use of carbamide peroxide injection series for virus inactivation in the treatment of blood vessel plaque, leukemia, AIDS and hepatitis, etc. The invention utilizes the affinity of photosensitizers to blood vessel plaque focus, leukemia cells, tumor, and/or virus, which is several times higher than that to normal tissues, so as to destroy focus cells or virus by generating sufficient singlet oxygen ( | 09-25-2014 |
| 20150051288 | Methods and Compositions for Treatment of Autism - Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder. | 02-19-2015 |
| 20150148422 | METHOD FOR PRESERVING FOOD AND METHOD FOR CLEANING SURFACES - A method for using urea sulfate as an anti-microbial agent, anti-mold agent, anti-fungal agent, and pH adjusting compound with the benefit of adding nitrogen and sulfur to the food supply. Urea sulfate provides a fundamental contribution to feed hygiene, as it suppresses the growth of mold and thus restricts the potential effect of mycotoxins. Consequently, feed safety is improved by adding this compound. | 05-28-2015 |
| 20150359224 | STABILIZED AND ACTIVATED BROMINE SOLUTIONS AS A BIOCIDE AND AS AN ANTIFOULING AGENT - The invention provides a process of removing or preventing biofouling, particularly on surfaces of industrial and agricultural equipment in contact with aqueous liquids. The process employs an antifouling composition of stabilized active halogen having a low pH. | 12-17-2015 |
| 20160045460 | HIGHLY PROTONATED HYDRONIUM AND CARBAMIDE AS A SKIN SANITIZING AND WOUND HEALING SOLUTION - A water-based, alcohol-free, skin sanitizing and wound healing solution with a natural skin softener, where the nature of the biocidal enhancer used in the process of making the solution significantly increases efficacy while simultaneously enabling much more economical manufacturing, processing and transportation of the product. As the present solution is water-based, no further moisturizing additives are required, and those with sensitive skin, diabetes, allergies or religious beliefs are able to use the product without concern. | 02-18-2016 |
| 20190142770 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | 05-16-2019 |
| 20190142771 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE | 05-16-2019 |
| 514589000 | Nitro or nitroso bonded directly to amino nitrogen (e.g., nitramine, nitrosamine, nitro-urea, etc.) | 2 |
| 20080221214 | Process for the preparation of "Urchym" a urease and alpha-chymotrypsin enzyme inhibitory drug - The present invention relates to the compound N-4-nitrophenyl-N′-4′-nitrophenylurea as a urease and α-chymotrypsin (anti HCV) enzyme inhibitory drug named “Urchym”. N-4-nitrophenyl-N′-4′-nitrophenylurea is prepared and screened for their urease and α-chymotrypsin inhibition effects, the said compound, showed strong urease inhibition (IC | 09-11-2008 |
| 20160136116 | Carmustine Pharmaceutical Composition - The present invention provides pharmaceutical formulations of lyophilized carmustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized carmustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with carmustine, such as neoplastic diseases. | 05-19-2016 |
| 514590000 | Carbazides or semicarbazides (i.e., N-N-C(=O)-N containing) | 2 |
| 20100249238 | PHARMACEUTICAL COMPOSITIONS COMPRISING SEMICARBAZONES AND THIOSEMICARBAZONES AND METHOD FOR TREATING INFLAMMATORY, PAINFUL AND FEBRILE CONDITIONS AND PREVENTING SIGNS AND SYMPTOMS OF INFLAMMATION - The present patent application refers to pharmaceutical compositions comprising at least a semicarbazone or a thiosemicarbazone, or a pharmaceutically acceptable salt, hydrated or solvated thereof, for the treatment of inflammatory, febrile and painful inflammatory conditions, inflammatory edema and peripheral or central neurophatic painful conditions or prevention of signs and symptoms of inflammation. Claim also pharmaceutical compositions comprising at least a semicarbazone, or a thiosemicarbazone, or a pharmaceutically acceptable salt, hydrated or solvated thereof and a therapeutically effective amount of these compounds, mixed or included in a pharmaceutically acceptable carrier or excipient or a thiosemicarbazone is provided as sustained or controlled release systems for human and veterinary use in solutions or in the solid state. | 09-30-2010 |
| 20220133659 | THERAPEUTIC AGENT FOR CORNEAL DISEASES - The present invention relates to a novel means for treating corneal diseases. The present invention provides a therapeutic agent for corneal diseases, containing a compound represented by the following formula (I): | 05-05-2022 |
| 514592000 | Sulfur attached directly to urea nitrogen by nonionic bonding | 12 |
| 20080262088 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR TREATING METABOLIC DISORDERS AND DIABETES - Disclosed herein are methods, compounds and compositions for preventing or treating a pancreatic disorder, including diabetes mellitus (e.g. type 1 and/or type 2 diabetes). The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for improving or at least stabilizing pancreatic function(s) and for the prevention and/or treatment of metabolic syndrome and its components. The invention further relates to methods, compounds and compositions for the prevention and/or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in patients in need thereof, including diabetic patients. | 10-23-2008 |
| 20090137680 | NOVEL NON-SELECTIVE CATION CHANNEL IN NEURONAL CELLS AND METHOD FOR TREATING BRAIN SWELLING - The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NC | 05-28-2009 |
| 514593000 | Sulfur is part of a substituent which contains additional nitrogen | 10 |
| 20100273886 | FORMULATIONS AND METHODS FOR LYOPHILIZATION AND LYOPHILATES PROVIDED THEREBY - The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided. | 10-28-2010 |
| 20110034560 | LIQUID FORMULATIONS OF COMPOUNDS ACTIVE AT SULFONYLUREA RECEPTORS - The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intra-venous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide. | 02-10-2011 |
| 20110288178 | RADIOPROTECTIVE AGENTS - Provided herein are methods, for reducing, preventing, mitigating and treating damage caused by radiation. The methods comprise delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation or to mitigate apoptosis. The compounds comprise glyburide or other sulfonylurea hypoglycemic compounds or potassium channel inhibitors. | 11-24-2011 |
| 20120225947 | RETINAL NEUROPROTECTION BY ION CHANNEL BLOCKERS REGULATED BY THE SUR SUBUNIT - The present invention relates to the use of blockers of ion channels regulated by the SUR subunit, for the treatment and/or prevention of eye diseases associated with ischemia and/or retinal excitotoxicity. | 09-06-2012 |
| 20130203853 | METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE AND OTHER DRUGS - Methods of administering glyburide, or other drug, are disclosed. The novel methods disclosed herein include intravenous methods of administering glyburide, or other drug, over periods of more than an hour, preferably over periods of about 72 hours. The novel methods include administering a bolus of glyburide, or other drug, followed by a first continuous infusion administration of glyburide, or other drug; and optionally a second or further bolus administration of glyburide, or other drug, and/or a second or further continuous infusion administration of glyburide, or other drug. These methods are effective to rapidly achieve a desired level of glyburide, or other drug, and to provide a substantially steady level of glyburide, or other drug, over a desired period of time. The methods disclosed herein may be useful for treating a subject in need of treatment for, e.g., acute stroke (ischemic and hemorrhagic), traumatic brain injury (TBI), spinal cord injury (SCI), myocardial infarction (MI), shock (including hemorrhagic shock), organ ischemia, and ventricular arrhythmias. These methods provide for the rapid achievement and maintenance of therapeutic glyburide, or other drug, plasma levels over an extended period of time, and further avoid excessive levels of drug and so avoid possible drug side-effects. | 08-08-2013 |
| 20140051761 | KATP ANTAGONISTS (GLIBENGLAMID) FOR USE FOR PROMOTING GROWTH AND/OR TREATING HYPERGLYCAEMIA OF A PREMATURE INFANT - The present invention relates to pharmaceutical compositions comprising an ATP-sensitive potassium (K ATP) channel antagonist (e.g., sulfonylureas, meglitinides) and methods for treating hyperglycaemia and/or promoting growth of a premature and/or small for gestational age infant. | 02-20-2014 |
| 20140378548 | INHIBITOR OF TRPM-4 ION CHANNEL FOR TREATING OR PREVENTING NEURODEGENERATION - The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a neurodegenerative disease, such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, or a myotrophic lateral sclerosis, in a subject. The invention also provides a pharmaceutical composition comprising a TRPM4 inhibitory compound. The invention further relates to in vitro methods for identifying pharmaceutically active compounds that are useful for treating or preventing a neurodegenerative disease. | 12-25-2014 |
| 20150051289 | LIQUID FORMULATIONS OF HYPOGLYCAEMIC SULFONAMIDES - The present invention relates to a liquid pharmaceutical formulation of hypoglycaemic sulfonamide, intended for oral or ophthalmic administration. The present invention relates in particular to an oral formulation particularly suitable for paediatric use. | 02-19-2015 |
| 20150141516 | FORMULATIONS AND METHODS FOR LYOPHILIZATION AND LYOPHILATES PROVIDED THEREBY - The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided. | 05-21-2015 |
| 20160030370 | METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE - The present disclosure is drawn to a method of treating a patient in need of treatment, comprising identifying a patient in need of treatment for stroke, traumatic brain injury, spinal cord injury, myocardial infarction, shock, organ ischemia, ventricular arrhythmias, ischemic injury, or hypoxia/ischemia; administering a bolus of glyburide to the patient; and administering a continuous infusion of glyburide to the patient at from about 15 μg/hr and about 300 μg/hr, wherein the continuous infusion glyburide is administered for a period of time more than about 20 hours. | 02-04-2016 |
| 514594000 | Additional C=O bonded directly to urea nitrogen | 3 |
| 20100280124 | ACYL-UREA DERIVATIVES AND USES THEREOF - Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilepticus, chemically-induced convulsions and/or seizure disorders, febrile convulsions conditions, metabolic disturbances and a sustenance withdrawal conditions, are provided. Also provided are uses of these and other acyl-urea containing compounds in the treatment of neurological diseases and disorders. | 11-04-2010 |
| 20140066514 | Veterinary Compositions For Controlling Ecto- And Endoparasites In Bovines, Use Of These Compositions, Use Of IGR Substances Associated With Microminerals, Method For Controlling Ecto- And Endoparasites In Bovines And Kit - Veterinary compositions are described for controlling ecto- and endo-parasites in animals, such as bovine. The compositions contain an IGR compound(s) or a benzoyl substituted urea(s) along with a mineral mix and at least one carrier. | 03-06-2014 |
| 20160000073 | FLUID BAIT FORMULATIONS AND THEIR USE WITH ACTIVE TERMITE INFESTATION - The subject invention provides fluid formulations for use in controlling a population of a pest once it has been detected Specifically, the subject invention pertains to a fluid bait formulation comprising a feed medium impregnated with at least one active ingredient and a liquid carrier. The invention is based on the concept of providing a unique fluid bait formulation that can be injected into a termite infestation site, where an effective amount of AI(s) is presented to the termite population, even following dehydration of the formulation, to control the termite population. | 01-07-2016 |
| 514595000 | Benzene ring containing | 25 |
| 20080221215 | ANTIVIRAL INHIBITION OF CAPSID PROTEINS - Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing mortality associated with AIDS with a compound that binds to the apical cleft near the C-terminal end of the N-terminal domain of the HIV-1 capsid protein are provided. Derivatives of CAP-1, CAP-2, CAP-3, CAP-4, CAP-5, CAP-6 and CAP-7 are described that bind to the apical cleft of the N-terminal domain of the HIV-1 capsid protein and inhibit proper assembly of the core particle. | 09-11-2008 |
| 20080234383 | Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same - This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease. | 09-25-2008 |
| 20090082456 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases. | 03-26-2009 |
| 20100048711 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans,trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 02-25-2010 |
| 20100130615 | SULFONYLUREA INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new sulfonylurea inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof. | 05-27-2010 |
| 20100179223 | Compounds, Compositions, and Methods for the Treatment of Synucleinopathies - Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment. | 07-15-2010 |
| 20120083532 | NOVEL USES - The present invention relates to the use of a compound represented by the general formula (I), and pharmaceutically acceptable salts thereof, wherein: n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, a thioether group, and an amino group, wherein at least two of R | 04-05-2012 |
| 20120088837 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF - Compounds of the formula I: | 04-12-2012 |
| 514596000 | Benzene ring bonded directly to urea nitrogen | 17 |
| 20080255239 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS - Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein. | 10-16-2008 |
| 20090023813 | Diphenyl Urea Derivatives - The invention relates to novel specifically trifluoromethyl and halogen substituted 1,3-diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects like the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives. | 01-22-2009 |
| 20100105777 | AMIDE OR THIOAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PAIN - The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for treatment of pain and disorders related thereto, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 04-29-2010 |
| 20100222431 | NOVEL PHENYLUREA INHIBITORS OF THE SOAT-1 ENZYME AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel phenylurea compounds of formula (I): | 09-02-2010 |
| 20100261796 | Use of Novel Compounds for IBD Treatment - The present invention relates to use of novel compounds for the manufacture of a medicament for treatment of inflammatory bowel disease (IBD) as well as to a method for treatment of IBD, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 10-14-2010 |
| 20110021633 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 01-27-2011 |
| 20140045944 | SYNERGISTIC ANTIMICROBIAL COMPOSITION - A synergistic antimicrobial composition containing 3-iodo-2-propynyl-butylcarbamate and fluometuron. | 02-13-2014 |
| 20150065575 | S100A8/A9 as a Diagnostic Marker and a Therapeutic Target - Determinations of the level of expression of S100A8/A9 protein serve as a prognostic indicator of the therapeutic response to a given type of chemotherapy treatment and as a monitoring indicator of the effectiveness of an on-going chemotherapy treatment for the treatment of breast cancer in human patients. Kits can be used for performing these determinations. | 03-05-2015 |
| 20150351405 | Antimicrobial Abrasive Cream Type Cleaning Compositions for Inanimate Hard Surfaces - The present invention provides aqueous alkaline, storage stable, abrasive containing hard surface treatment compositions which provide good cleaning to a treated hard surface, and concurrently a useful sanitizing or disinfecting benefit to such treated surfaces, wherein the compositions comprise: 0.01-15% wt. of at least one anionic surfactant and at least one nonionic surfactant, and preferably wherein the amount of the at least one anionic surfactant is in excess of the amount of the at least one nonionic surfactant; 0.1-50% wt. of one or more inorganic abrasive particulate materials which are based on inorganic carbonate compounds; a thickener; at least one non-cationic germicide constituent, which preferably are one or more compounds selected from the group consisting of: parachlorometaxylenol, and halogenated carbanilides (e.g., 3,4,4′-trichlorocarbanilide (also referred to as Triclocarban® or TCC), 3-trifluoromethyl-4,4-dichlorocarbanilide, and 3,3,4-trichlorocarbanilide; and, water, wherein the compositions preferably exhibit a pH in the range of 7-10.5, a viscosity of 1000-3000 cPs, when measured at 25° C., and wherein the compositions provide an antimicrobial benefit to treated hard surfaces. | 12-10-2015 |
| 20160008302 | COMPOUNDS AND METHODS FOR TREATING ABERRANT ADRENOCORTICAL CELL DISORDERS | 01-14-2016 |
| 514597000 | Benzene ring is part of a substituent which contains nitrogen | 5 |
| 20110144208 | COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE BIS-UREA DERIVATIVE - The present disclosure relates to cosmetic compositions comprising at least one continuous liquid fatty phase comprising at least one compound of formula (I), | 06-16-2011 |
| 20130065963 | Histone Deacetylase Inhibitors and Methods of Use Thereof - The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention. | 03-14-2013 |
| 20130338231 | NOVEL CONJUGATION REAGENTS - The invention provides compound of the general formula: | 12-19-2013 |
| 20140256819 | KINASE INHIBITORS - The present invention relates to compounds of formula I | 09-11-2014 |
| 20150342911 | METHOD FOR TREATING CHIKUNGUNYA VIRUS INFECTION - Disclosed herein is a method for the treatment of an infection with, or disease caused by, Chikungunya virus in a subject. The method includes administering to the subject a therapeutically effective amount of suramin as the active agent. | 12-03-2015 |
| 514598000 | Benzene ring is part of a substituent which contains oxygen | 2 |
| 20090197965 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE - Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment. | 08-06-2009 |
| 20140288183 | Compounds and Compositions for use a Modulators of Tau Aggregation and Alleviation of Tauopathies - This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia. | 09-25-2014 |
